Jun 27, 2001|
Hoechst: Hope for the best
The sales figures for the first five months of Hoechst (now Aventis Pharma Ltd) are bit disappointing. While the company had reported a growth of 10.8% in the first quarter (January to March) of the current year, the first five months have seen a sales growth of only 5%. This implies that sales have infact shown degrowth of over 2% in the months of April and May. The volatility in sales may be due to recent product restructuring carried out by the company.
The company's product portfolio now includes a rather unique combination of old, mature brands as well as new product launches, which have met with remarkable success as shown in the table below. The strategy for the company going forward is to concentrate on these strategic brands to ensure growth in the future.
(*Jan- March'Q1 01-02 over 00-01)
|Strategic New Products
....Access to parent's pipeline and strong brands remain trump cards
Aventis Pharma (which holds 50.1% stake) has an enviably rich pipeline of products and the Indian company is expected to benefit from that in the coming years. At this point of time, it seems that the parent company would continue to give fast access to its worldwide product portfolio.
The older products of the company, though growing at a slow pace command significant brand value. Some of the products from the company's stable include Avil, Daonil, Soframycin, Novalgin, which are now household names.
Restructuring has helped...
Rationalization of products coupled with aggressive growth in new products helped the company reduce its DPCO coverage to 40% from 60% couple of years back. New product contribution to the total domestic formulations sales now contribute more than 16%, up from 6% a couple of years back. Further, rationalization of expenses, particularly staff cost has also helped in achieving more than 200 basis point improvement in its operating margin.
The recent sale of the company's Mulund facility (as part of restructuring) is expected to generate considerable cash flows for the company. The company has already reduced its debt to the tune of Rs 225 m in the last year. With additional cash flows from sale of this property, the debt burden is expected to reduce significantly in the current year.
The new Goa plant of the company has already been inspected by German FDA. It is expected that HMR's facilities would be used as a global source supply for its parent company. (Particularly for an intermediate of articaine hydrochloride and a key intermediate for ramipril).
Synergies with Rhone Poulenc Rorer (RPR)
HMR has 49% stake in RPR India and the balance is held by the parent company. RPR's strong portfolio in cardiovascular and oncology segments would help in the carving a niche in these high growth segments.
At the current market price of Rs 403, HMR trades at 21 times its FY2002E earnings, which is lower to its peers in the industry. The reason for the same seems to be successive disappointments due to non-relaxation of DPCO in favour of the company and drop in sales growth due to product restructuring.
HMR- A comparative valuation
(*based on latest full year results)
|Market Capitalisation (Rs in mn)
|Market Cap/Sales (x)
|P/e-2002 E (x)
To summarize, the triggers for the stock are the expected outsourcing by the parent company 6-8 months down the line, growth in strategic new products, further introduction of new products and expected dilution of DPCO. Though, the company has been moving in the right direction, it needs to be seen how well the restructuring exercise pays off. Further, though the company has been able to command premium price for its strategic products till date, it might face stiff price competition from domestic players. Further, the transfer pricing norms of new products imported from Aventis remain a cause of concern.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407